Amylyx Q3 net loss narrows to $34.4M; cash $344M after $191M offering

Amylyx Pharmaceuticals, Inc.

2025-Q3 EPS reported -$1.25

Net loss $34.4M ($0.37/sh) vs $72.7M ($1.07/sh) in Q3 2024; R&D $19.9M, SG&A $16.2M.
Cash and securities $344M at Sept 30, up from $180.8M at June 30; cash runway into 2028.
Phase 3 LUCIDITY trial of avexitide recruitment completion expected Q1 2026; topline data Q3 2026.
Phase 1 LUMINA trial of AMX0114 in ALS fully enrolled cohort 1; early data at Dec symposium.
Plan to initiate Phase 3 trial of AMX0035 in Wolfram syndrome H2 2026 pending FDA alignment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.